The claim
Peptides are short chains of amino acids that act as signals in the body. They are sold as a way to recover faster, lose stubborn fat, sleep more deeply, look younger, and slow aging. The pitch usually frames them as instructions to your body rather than hormone replacement, which makes them sound gentler than a prescription hormone.
What the evidence supports
- A small number of peptides are FDA-approved drugs for specific uses. For example, as of September 2026, elamipretide has accelerated approval for a rare, serious condition called Barth syndrome. That approval does not extend to energy or aging in a healthy adult.
- Some of the compounds sold in clinics do what they are designed to do at the molecular level in people. In one 2006 study of healthy adults, a long-acting form of CJC-1295 raised growth hormone and IGF-1 levels. That is a result about hormone levels, not about how people looked, slept, or felt.
- In human studies, kisspeptin activates the pathway that drives the sex hormones. In the US it is an investigational drug.
- A copper peptide, GHK-Cu, has small human studies for topical use on skin.
What the evidence does not establish
- That raising growth hormone signaling in healthy midlife adults improves outcomes people care about, or that it is safe over years.
- That tissue-repair peptides such as BPC-157 and TB-500 heal tendons, joints, or the gut in people. The mechanistic support is mostly from rodent and cell studies.
- That any peptide slows aging in humans.
- That combinations, often sold as "stacks," work better than single compounds. For almost every combination sold, no controlled human evidence exists.
- That a prescription means a product is approved, verified, or free of quality problems. Compounded products follow different rules from approved drugs.
Who is selling it
Telehealth programs and anti-aging clinics, compounding pharmacies, and online sellers that label products "for research use only." Each has a commercial stake in your saying yes. A 2024 analysis of semaglutide vials sold online without a prescription found endotoxin in every sample and purity far below what the labels claimed. That is one study of one product type, and it does not show every peptide product is contaminated. It does show that a label is not proof.
Where each compound stands, as of September 2026
| Compound | Regulatory bucket | What to know |
|---|---|---|
| Elamipretide (SS-31) | Approved | Accelerated approval 2025 for Barth syndrome only; single specialty pharmacy. Not an approved longevity or energy therapy. |
| Sermorelin | Unsettled | Prior FDA drug history. Nominated for the FDA 503A bulks list, filed in Category 3, not on the list as of Sept 2026; 'compoundable' overstates the FDA sources. Bucket withheld pending Peters/Compliance ruling (Ch12 CH12-003). |
| CJC-1295 | Unsettled | Removed from FDA Category 2 list Sept 2024 after nominators withdrew; not on 503A bulks list as of Sept 2026; FDA still lists safety concerns. Regulatory gray zone. |
| Ipamorelin | Unsettled | Availability varies by clinic; bucket check required before relying on legality. |
| BPC-157 | Under review | Before an FDA advisory panel July 2026; non-binding committee recommendation to allow compounding again; no final FDA ruling at time of writing; FDA's own briefing proposed excluding some substances. |
| MOTS-c | Under review | Before an FDA advisory panel July 2026; non-binding committee recommendation; no final FDA ruling at time of writing; FDA's own briefing proposed excluding some substances. |
| Kisspeptin | Unsettled | Access outside research settings is limited; treat commercial 'kisspeptin therapy' claims with skepticism. |
| GHK-Cu (copper peptide) | Unsettled | Mostly relevant as a topical for skin; different regulatory category from injectables. Human skin data are small studies; connective-tissue claims are preclinical. |
Regulatory status changes. Check the FDA's current lists before relying on anything here. The full directory is at the peptide status page.
Questions worth taking to a qualified clinician
- Is this the approved product, and is this an approved use?
- Which regulatory bucket is it in today (Approved, Compoundable, Under review, or Research-only), in writing?
- What human evidence supports the specific result being promised, and how strong is it?
- Where is it made, and can I see batch testing for the exact lot?
- What baseline labs should exist before anyone discusses this with me, and who reads them?
- What would you suggest if this product did not exist?
ManopauseMD verdict
A small number of peptide drugs are approved for specific uses. For most of what is sold to healthy adults, the mechanism or the marketing is ahead of the human outcomes.
Related
Educational information only, not medical advice, diagnosis, or treatment. Dr. Michael Peters is a retired physician and does not practice medicine. This page offers no personalized interpretation.